Loss to follow-up in the Australian HIV Observational Database

Abstract

Background

Loss to follow-up (LTFU) in HIV-positive cohorts is an important surrogate for interrupted clinical care, which can potentially influence the assessment of HIV disease status and outcomes. After preliminary evaluation of LTFU rates and patient characteristics, we evaluated the risk of mortality by LTFU status in a high-resource setting.

Methods

Rates of LTFU were measured in the Australian HIV Observational Database for a range of patient characteristics. Multivariate repeated measures regression methods were used to identify determinants of LTFU. Mortality by LTFU status was ascertained using linkage to the National Death Index. Survival following combination antiretroviral therapy initiation was investigated using the Kaplan–Meier (KM) method and Cox proportional hazards models.

Results

Of 3,413 patients included in this analysis, 1,632 (47.8%) had at least one episode of LTFU after enrolment. Multivariate predictors of LTFU included viral load (VL)>10,000 copies/ml (rate ratio [RR] 1.63; 95% CI 1.45, 1.84; ref ≤400), time under follow-up (per year; RR 1.03; 95% CI 1.02, 1.04) and prior LTFU (per episode; RR 1.15; 95% CI 1.06, 1.24). KM curves for survival were similar by LTFU status (P=0.484). LTFU was not associated with mortality in Cox proportional hazards models (univariate hazard ratio [HR] 0.93; 95% CI 0.69, 1.26) and multivariate HR 1.04 (95% CI 0.77, 1.43).

Conclusions

Increased risk of LTFU was identified amongst patients with potentially higher infectiousness. We did not find significant mortality risk associated with LTFU. This is consistent with timely re-engagement with treatment, possibly via high levels of unreported linkage to other health-care providers.

References

Brinkhof

M.W.

, Pujades-Rodriguez

, Egger

Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis.

PLoS ONE 2009; 4: e5790.

Dalal

R.P.

, Macphail

, Mqhayi

Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa.

J Acquir Immune Defic Syndr 2008; 47: 101–107.

Brennan

A.T.

, Maskew

, Sanne

, Fox

M.P.

The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa.

J Int AIDS Soc 2010; 13: 49.

Egger

, Spycher

B.D.

, Sidle

Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa.

PLoS Med 2011; 8: e1000390.

Edwards

J.K.

, Cole

S.R.

, Westreich

Loss to clinic and five-year mortality among HIV-infected antiretroviral therapy initiators.

PLoS ONE 2014; 9: e102305.

Horberg

M.A.

, Hurley

L.B.

, Silverberg

M.J.

, Klein

D.B.

, Quesenberry

C.P.

, Mugavero

M.J.

Missed office visits and risk of mortality among HIV-infected subjects in a large healthcare system in the United States.

AIDS Patient Care STDS 2013; 27: 442–449.

Lanoy

, Lewden

, Lievre

How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalite 2000 survey and death certificates.

HIV Med 2009; 10: 236–245.

Hill

, Bansi

, Sabin

Data linkage reduces loss to follow-up in an observational HIV cohort study.

J Clin Epidemiol 2010; 63: 1101–1109.

Mocroft

, Kirk

, Aldins

Loss to follow-up in an international, multicentre observational study.

HIV Med 2008; 9: 261–269.

10.

Porter

, Johnson

A.M.

, Phillips

A.N.

, Darbyshire

J.H.

The practical significance of potential biases in estimates of the AIDS incubation period distribution in the UK register of HIV seroconverters.

AIDS 1999; 13: 1943–1951.

11.

Simard

E.P.

, Pfeiffer

R.M.

, Engels

E.A.

Mortality due to cancer among people with AIDS: a novel approach using registry-linkage data and population attributable risk methods.

AIDS 2012; 26: 1311–1318.

12.

Fonseca

M.G.

, Coeli

C.M.

, de Fatima de Araujo Lucena

, Veloso

V.G.

, Carvalho

M.S.

Accuracy of a probabilistic record linkage strategy applied to identify deaths among cases reported to the Brazilian AIDS surveillance database.

Cad Saude Publica 2010; 26: 1431–1438.

13.

Centers for Disease Control and Prevention.

Electronic record linkage to identify deaths among persons with AIDS-District of Columbia, 2000–2005.

MMWR Morb Mortal Wkly Rep 2008; 57: 631–634.

14.

Jordan

W.C.

Reaching lost-to-care populations.

Clin Infect Dis 2007; 45 Suppl 4: S275–S280.

15.

Harding

, Krakauer

E.L.

, Sithole

, De Lima

, Selman

The ‘lost’ HIV population: time to refocus our clinical and research efforts.

AIDS 2009; 23: 145–146.

16.

Friis-Møller

, Sabin

C.A.

, Weber

Combination antiretroviral therapy and the risk of myocardial infarction.

N Engl J Med 2003; 349: 1993–2003.

17.

Cullen

B.L.

, Codere

, Wallace

L.A.

, Baguley

, Clutterbuck

D.J.

British Association for Sexual Health and HIV Scottish investigation 2010–2011: reasons for non-attendance in individuals lost to follow-up for HIV care for more than 12 months in Scotland.

Int J STD AIDS 2013; 24: 481–484.

18.

Lebouché

, Yazdanpanah

, Gerard

Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998.

HIV Med 2006; 7: 140–145.

19.

Falster

, Gelgor

, Shaik

Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment.

Sex Health 2008; 5: 141–154.

20.

Kirby Institute. Australian HIV Observational Database Annual Report 2013. (Accessed 6 June 2014.) Available from https://kirby.unsw.edu.au/sites/default/files/hiv/attachment/AHOD-Report-Sept2013.pdf.

21.

Pollio

D.E.

The relationship between transience and current life situation in the homeless services-using population.

Soc Work 1997; 42: 541–551.

22.

Tulloch

A.D.

, Fearon

, David

A.S.

Timing, prevalence, determinants and outcomes of homelessness among patients admitted to acute psychiatric wards.

Soc Psychiatry Psychiatr Epidemiol 2012; 47: 1181–1191.

23.

Chesney

M.A.

Factors affecting adherence to antiretroviral therapy.

Clin Infect Dis 2000; 30 Suppl 2: S171–S176.

24.

Keiser

, Spycher

, Rauch

Outcomes of antiretroviral therapy in the Swiss HIV Cohort Study: latent class analysis.

AIDS Behav 2012; 16: 245–255.

25.

Andrews

J.R.

, Wood

, Bekker

L.G.

, Middelkoop

, Walensky

R P.

Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care.

J Infect Dis 2012; 206: 543–551.

26.

Rachlis

, Brouwer

K.C.

, Mills

E.J.

, Hayes

, Kerr

, Hogg

R.S.

Migration and transmission of blood-borne infections among injection drug users: understanding the epidemiologic bridge.

Drug Alcohol Depend 2007; 90: 107–119.

27.

South

S.J.

, Crowder

K.D.

Residential mobility between cities and suburbs: race, suburbanization, and back-to-the-city moves.

Demography 1997; 34: 525–538.

28.

Wood

, Yip

, Gataric

Determinants of geographic mobility among participants in a population-based HIV/ AIDS drug treatment program.

Health Place 2000; 6: 33–40.

29.

Madden

H.C.

, Phillips-Howard

P.A.

, Hargreaves

S.C.

Access to HIV community services by vulnerable populations: evidence from an enhanced HIV/AIDS surveillance system.

AIDS Care 2011; 23: 542–549.

30.

German

, Davey

M.A.

, Latkin

C.A.

Residential transience and HIV risk behaviors among injection drug users.

AIDS Behav 2007; 11 Suppl: 21–30.

31.

Strathdee

S.A.

, Hallett

T.B.

, Bobrova

HIV and risk environment for injecting drug users: the past, present, and future.

Lancet 2010; 376: 268–284.

32.

Australasian Society for HIV Medicine. 2013 Antiretroviral Guidelines with Australian Commentary 2014. (Updated 2 December 2013. Accessed 11 March 2014.) Available from http://arv.ashm.org.au/arv-guidelines/initiating-art-in-treatment-naive-patients.

33.

Australian Government Department of Human Services. Highly Specialised Drugs (HSD) program: Commonwealth of Australia; 2014. (Updated 19 December 2013. Accessed 12 May 2014.) Available from http://www.medicareaustralia.gov.au/provider/pbs/highly-specialised-drugs/#N100E3.

34.

Australian Government Department of Health. Browse by Section 100 Item List: Highly Specialised Drugs program; 2014. (Accessed 12 May 2014.) Available from http://pbs.gov.au/browse/section100-hb?initial=a.